August 5, 2014 11:09 AM

Durham’s BioCryst falls short of analyst expectations in Q2

Durham drug developer BioCryst Pharmaceuticals revenue doubled in the second quarter as the company got a boost from federal funding for its treatment for Marburg virus infection, which is almost indistinguishable from Ebola virus fever.

Related content